Company profile

Gan & Lee Pharmaceuticals

Insulin / GLP-1 peptide therapeutics

603087 · SSE · China

Public Market Listing

603087SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Gan & Lee Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
GZR18
Phase 3
GLP-1 receptorPeptide
Obesity
GZR33
Phase 3
Insulin receptor (basal)Peptide
Type 2 Diabetes
GZR101
Phase 2
Insulin receptor (basal)Peptide
Type 2 Diabetes
GZR102
Phase 1
Insulin receptor / GLP-1 receptor (combination)Peptide
Obesity

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.